nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP2D6—Lomustine—hematologic cancer	0.0394	0.0738	CbGbCtD
Cevimeline—CYP2D6—Idarubicin—hematologic cancer	0.0352	0.0658	CbGbCtD
Cevimeline—CYP2D6—Hydroxyurea—hematologic cancer	0.0299	0.0559	CbGbCtD
Cevimeline—CYP3A4—Bexarotene—hematologic cancer	0.027	0.0505	CbGbCtD
Cevimeline—CYP2D6—Bortezomib—hematologic cancer	0.026	0.0487	CbGbCtD
Cevimeline—CYP3A4—Busulfan—hematologic cancer	0.0251	0.0469	CbGbCtD
Cevimeline—CYP3A4—Lomustine—hematologic cancer	0.0251	0.0469	CbGbCtD
Cevimeline—CYP3A4—Thiotepa—hematologic cancer	0.0224	0.0418	CbGbCtD
Cevimeline—CYP2D6—Imatinib—hematologic cancer	0.0191	0.0356	CbGbCtD
Cevimeline—CYP3A4—Methoxsalen—hematologic cancer	0.0174	0.0325	CbGbCtD
Cevimeline—CYP2D6—Nilotinib—hematologic cancer	0.0173	0.0324	CbGbCtD
Cevimeline—CYP2D6—Vinorelbine—hematologic cancer	0.0172	0.0321	CbGbCtD
Cevimeline—CYP3A4—Bortezomib—hematologic cancer	0.0165	0.0309	CbGbCtD
Cevimeline—CYP3A4—Daunorubicin—hematologic cancer	0.0158	0.0296	CbGbCtD
Cevimeline—CYP3A4—Cytarabine—hematologic cancer	0.014	0.0261	CbGbCtD
Cevimeline—CYP3A4—Teniposide—hematologic cancer	0.0137	0.0257	CbGbCtD
Cevimeline—CYP3A4—Ifosfamide—hematologic cancer	0.0127	0.0237	CbGbCtD
Cevimeline—CYP3A4—Imatinib—hematologic cancer	0.0121	0.0227	CbGbCtD
Cevimeline—CYP3A4—Ruxolitinib—hematologic cancer	0.0114	0.0213	CbGbCtD
Cevimeline—CYP3A4—Nilotinib—hematologic cancer	0.011	0.0206	CbGbCtD
Cevimeline—CYP3A4—Vinorelbine—hematologic cancer	0.0109	0.0204	CbGbCtD
Cevimeline—CYP2D6—Vinblastine—hematologic cancer	0.0106	0.0198	CbGbCtD
Cevimeline—CYP3A4—Triamcinolone—hematologic cancer	0.00998	0.0187	CbGbCtD
Cevimeline—CYP3A4—Dasatinib—hematologic cancer	0.00973	0.0182	CbGbCtD
Cevimeline—CYP3A4—Mitoxantrone—hematologic cancer	0.00961	0.018	CbGbCtD
Cevimeline—CYP3A4—Betamethasone—hematologic cancer	0.00857	0.016	CbGbCtD
Cevimeline—CYP3A4—Prednisolone—hematologic cancer	0.00845	0.0158	CbGbCtD
Cevimeline—CYP3A4—Prednisone—hematologic cancer	0.00798	0.0149	CbGbCtD
Cevimeline—CYP2D6—Dexamethasone—hematologic cancer	0.00784	0.0147	CbGbCtD
Cevimeline—CYP3A4—Irinotecan—hematologic cancer	0.00757	0.0142	CbGbCtD
Cevimeline—CYP3A4—Vinblastine—hematologic cancer	0.00673	0.0126	CbGbCtD
Cevimeline—CYP3A4—Vincristine—hematologic cancer	0.00661	0.0124	CbGbCtD
Cevimeline—CYP2D6—Doxorubicin—hematologic cancer	0.0065	0.0122	CbGbCtD
Cevimeline—CYP3A4—Etoposide—hematologic cancer	0.00606	0.0113	CbGbCtD
Cevimeline—CYP3A4—Dexamethasone—hematologic cancer	0.00498	0.00932	CbGbCtD
Cevimeline—CYP3A4—Doxorubicin—hematologic cancer	0.00413	0.00773	CbGbCtD
Cevimeline—Visual impairment—Doxorubicin—hematologic cancer	1.96e-05	4.64e-05	CcSEcCtD
Cevimeline—Nervous system disorder—Prednisone—hematologic cancer	1.95e-05	4.63e-05	CcSEcCtD
Cevimeline—Tachycardia—Prednisone—hematologic cancer	1.94e-05	4.61e-05	CcSEcCtD
Cevimeline—Alopecia—Epirubicin—hematologic cancer	1.94e-05	4.6e-05	CcSEcCtD
Cevimeline—Skin disorder—Prednisone—hematologic cancer	1.94e-05	4.59e-05	CcSEcCtD
Cevimeline—Nausea—Gemcitabine—hematologic cancer	1.93e-05	4.59e-05	CcSEcCtD
Cevimeline—Vomiting—Cisplatin—hematologic cancer	1.93e-05	4.58e-05	CcSEcCtD
Cevimeline—Hyperhidrosis—Prednisone—hematologic cancer	1.93e-05	4.57e-05	CcSEcCtD
Cevimeline—Rash—Cisplatin—hematologic cancer	1.91e-05	4.54e-05	CcSEcCtD
Cevimeline—Dermatitis—Cisplatin—hematologic cancer	1.91e-05	4.53e-05	CcSEcCtD
Cevimeline—Malnutrition—Epirubicin—hematologic cancer	1.91e-05	4.53e-05	CcSEcCtD
Cevimeline—Diarrhoea—Etoposide—hematologic cancer	1.9e-05	4.51e-05	CcSEcCtD
Cevimeline—Anorexia—Prednisone—hematologic cancer	1.9e-05	4.5e-05	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—hematologic cancer	1.9e-05	4.5e-05	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—hematologic cancer	1.89e-05	4.49e-05	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—hematologic cancer	1.89e-05	4.49e-05	CcSEcCtD
Cevimeline—Anaemia—Methotrexate—hematologic cancer	1.89e-05	4.47e-05	CcSEcCtD
Cevimeline—Feeling abnormal—Dexamethasone—hematologic cancer	1.89e-05	4.47e-05	CcSEcCtD
Cevimeline—Feeling abnormal—Betamethasone—hematologic cancer	1.89e-05	4.47e-05	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—hematologic cancer	1.88e-05	4.47e-05	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—hematologic cancer	1.88e-05	4.47e-05	CcSEcCtD
Cevimeline—Flatulence—Epirubicin—hematologic cancer	1.88e-05	4.46e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.87e-05	4.44e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Betamethasone—hematologic cancer	1.87e-05	4.44e-05	CcSEcCtD
Cevimeline—Dysgeusia—Epirubicin—hematologic cancer	1.87e-05	4.43e-05	CcSEcCtD
Cevimeline—Hypersensitivity—Triamcinolone—hematologic cancer	1.86e-05	4.41e-05	CcSEcCtD
Cevimeline—Back pain—Epirubicin—hematologic cancer	1.85e-05	4.38e-05	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—hematologic cancer	1.84e-05	4.37e-05	CcSEcCtD
Cevimeline—Malaise—Methotrexate—hematologic cancer	1.84e-05	4.36e-05	CcSEcCtD
Cevimeline—Dizziness—Etoposide—hematologic cancer	1.84e-05	4.36e-05	CcSEcCtD
Cevimeline—Muscle spasms—Epirubicin—hematologic cancer	1.84e-05	4.35e-05	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—hematologic cancer	1.83e-05	4.35e-05	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—hematologic cancer	1.83e-05	4.33e-05	CcSEcCtD
Cevimeline—Chills—Doxorubicin—hematologic cancer	1.82e-05	4.32e-05	CcSEcCtD
Cevimeline—Urticaria—Dexamethasone—hematologic cancer	1.82e-05	4.31e-05	CcSEcCtD
Cevimeline—Urticaria—Betamethasone—hematologic cancer	1.82e-05	4.31e-05	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.82e-05	4.3e-05	CcSEcCtD
Cevimeline—Dizziness—Prednisolone—hematologic cancer	1.81e-05	4.3e-05	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—hematologic cancer	1.81e-05	4.3e-05	CcSEcCtD
Cevimeline—Asthenia—Triamcinolone—hematologic cancer	1.81e-05	4.29e-05	CcSEcCtD
Cevimeline—Abdominal pain—Dexamethasone—hematologic cancer	1.81e-05	4.29e-05	CcSEcCtD
Cevimeline—Body temperature increased—Betamethasone—hematologic cancer	1.81e-05	4.29e-05	CcSEcCtD
Cevimeline—Abdominal pain—Betamethasone—hematologic cancer	1.81e-05	4.29e-05	CcSEcCtD
Cevimeline—Body temperature increased—Dexamethasone—hematologic cancer	1.81e-05	4.29e-05	CcSEcCtD
Cevimeline—Nausea—Cisplatin—hematologic cancer	1.8e-05	4.27e-05	CcSEcCtD
Cevimeline—Insomnia—Prednisone—hematologic cancer	1.8e-05	4.27e-05	CcSEcCtD
Cevimeline—Alopecia—Doxorubicin—hematologic cancer	1.79e-05	4.25e-05	CcSEcCtD
Cevimeline—Paraesthesia—Prednisone—hematologic cancer	1.79e-05	4.24e-05	CcSEcCtD
Cevimeline—Pruritus—Triamcinolone—hematologic cancer	1.78e-05	4.23e-05	CcSEcCtD
Cevimeline—Cough—Methotrexate—hematologic cancer	1.78e-05	4.22e-05	CcSEcCtD
Cevimeline—Ill-defined disorder—Epirubicin—hematologic cancer	1.77e-05	4.2e-05	CcSEcCtD
Cevimeline—Convulsion—Methotrexate—hematologic cancer	1.77e-05	4.19e-05	CcSEcCtD
Cevimeline—Vomiting—Etoposide—hematologic cancer	1.77e-05	4.19e-05	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—hematologic cancer	1.77e-05	4.19e-05	CcSEcCtD
Cevimeline—Anaemia—Epirubicin—hematologic cancer	1.76e-05	4.19e-05	CcSEcCtD
Cevimeline—Agitation—Epirubicin—hematologic cancer	1.75e-05	4.16e-05	CcSEcCtD
Cevimeline—Dyspepsia—Prednisone—hematologic cancer	1.75e-05	4.16e-05	CcSEcCtD
Cevimeline—Rash—Etoposide—hematologic cancer	1.75e-05	4.16e-05	CcSEcCtD
Cevimeline—Dermatitis—Etoposide—hematologic cancer	1.75e-05	4.15e-05	CcSEcCtD
Cevimeline—Headache—Etoposide—hematologic cancer	1.74e-05	4.13e-05	CcSEcCtD
Cevimeline—Flatulence—Doxorubicin—hematologic cancer	1.74e-05	4.13e-05	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—hematologic cancer	1.74e-05	4.12e-05	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—hematologic cancer	1.74e-05	4.12e-05	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—hematologic cancer	1.74e-05	4.12e-05	CcSEcCtD
Cevimeline—Decreased appetite—Prednisone—hematologic cancer	1.73e-05	4.11e-05	CcSEcCtD
Cevimeline—Dysgeusia—Doxorubicin—hematologic cancer	1.73e-05	4.1e-05	CcSEcCtD
Cevimeline—Rash—Prednisolone—hematologic cancer	1.73e-05	4.1e-05	CcSEcCtD
Cevimeline—Dermatitis—Prednisolone—hematologic cancer	1.73e-05	4.1e-05	CcSEcCtD
Cevimeline—Malaise—Epirubicin—hematologic cancer	1.72e-05	4.08e-05	CcSEcCtD
Cevimeline—Fatigue—Prednisone—hematologic cancer	1.72e-05	4.07e-05	CcSEcCtD
Cevimeline—Headache—Prednisolone—hematologic cancer	1.72e-05	4.07e-05	CcSEcCtD
Cevimeline—Discomfort—Methotrexate—hematologic cancer	1.72e-05	4.07e-05	CcSEcCtD
Cevimeline—Vertigo—Epirubicin—hematologic cancer	1.72e-05	4.07e-05	CcSEcCtD
Cevimeline—Syncope—Epirubicin—hematologic cancer	1.71e-05	4.06e-05	CcSEcCtD
Cevimeline—Leukopenia—Epirubicin—hematologic cancer	1.71e-05	4.05e-05	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—hematologic cancer	1.71e-05	4.05e-05	CcSEcCtD
Cevimeline—Constipation—Prednisone—hematologic cancer	1.7e-05	4.04e-05	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—hematologic cancer	1.7e-05	4.03e-05	CcSEcCtD
Cevimeline—Palpitations—Epirubicin—hematologic cancer	1.69e-05	4e-05	CcSEcCtD
Cevimeline—Confusional state—Methotrexate—hematologic cancer	1.68e-05	3.98e-05	CcSEcCtD
Cevimeline—Loss of consciousness—Epirubicin—hematologic cancer	1.68e-05	3.98e-05	CcSEcCtD
Cevimeline—Dizziness—Triamcinolone—hematologic cancer	1.67e-05	3.95e-05	CcSEcCtD
Cevimeline—Cough—Epirubicin—hematologic cancer	1.67e-05	3.95e-05	CcSEcCtD
Cevimeline—Convulsion—Epirubicin—hematologic cancer	1.65e-05	3.92e-05	CcSEcCtD
Cevimeline—Infection—Methotrexate—hematologic cancer	1.65e-05	3.92e-05	CcSEcCtD
Cevimeline—Nausea—Etoposide—hematologic cancer	1.65e-05	3.92e-05	CcSEcCtD
Cevimeline—Hypertension—Epirubicin—hematologic cancer	1.65e-05	3.91e-05	CcSEcCtD
Cevimeline—Feeling abnormal—Prednisone—hematologic cancer	1.64e-05	3.89e-05	CcSEcCtD
Cevimeline—Asthenia—Dexamethasone—hematologic cancer	1.64e-05	3.89e-05	CcSEcCtD
Cevimeline—Asthenia—Betamethasone—hematologic cancer	1.64e-05	3.89e-05	CcSEcCtD
Cevimeline—Ill-defined disorder—Doxorubicin—hematologic cancer	1.64e-05	3.89e-05	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—hematologic cancer	1.63e-05	3.87e-05	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—hematologic cancer	1.63e-05	3.87e-05	CcSEcCtD
Cevimeline—Thrombocytopenia—Methotrexate—hematologic cancer	1.63e-05	3.87e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Prednisone—hematologic cancer	1.63e-05	3.86e-05	CcSEcCtD
Cevimeline—Nausea—Prednisolone—hematologic cancer	1.63e-05	3.86e-05	CcSEcCtD
Cevimeline—Arthralgia—Epirubicin—hematologic cancer	1.63e-05	3.85e-05	CcSEcCtD
Cevimeline—Chest pain—Epirubicin—hematologic cancer	1.63e-05	3.85e-05	CcSEcCtD
Cevimeline—Myalgia—Epirubicin—hematologic cancer	1.63e-05	3.85e-05	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—hematologic cancer	1.62e-05	3.85e-05	CcSEcCtD
Cevimeline—Anxiety—Epirubicin—hematologic cancer	1.62e-05	3.84e-05	CcSEcCtD
Cevimeline—Pruritus—Dexamethasone—hematologic cancer	1.62e-05	3.84e-05	CcSEcCtD
Cevimeline—Pruritus—Betamethasone—hematologic cancer	1.62e-05	3.84e-05	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—hematologic cancer	1.62e-05	3.84e-05	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—hematologic cancer	1.61e-05	3.82e-05	CcSEcCtD
Cevimeline—Discomfort—Epirubicin—hematologic cancer	1.61e-05	3.81e-05	CcSEcCtD
Cevimeline—Vomiting—Triamcinolone—hematologic cancer	1.6e-05	3.8e-05	CcSEcCtD
Cevimeline—Malaise—Doxorubicin—hematologic cancer	1.59e-05	3.78e-05	CcSEcCtD
Cevimeline—Rash—Triamcinolone—hematologic cancer	1.59e-05	3.77e-05	CcSEcCtD
Cevimeline—Dermatitis—Triamcinolone—hematologic cancer	1.59e-05	3.77e-05	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—hematologic cancer	1.59e-05	3.76e-05	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—hematologic cancer	1.59e-05	3.76e-05	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—hematologic cancer	1.58e-05	3.76e-05	CcSEcCtD
Cevimeline—Urticaria—Prednisone—hematologic cancer	1.58e-05	3.75e-05	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—hematologic cancer	1.58e-05	3.75e-05	CcSEcCtD
Cevimeline—Headache—Triamcinolone—hematologic cancer	1.58e-05	3.75e-05	CcSEcCtD
Cevimeline—Abdominal pain—Prednisone—hematologic cancer	1.58e-05	3.74e-05	CcSEcCtD
Cevimeline—Body temperature increased—Prednisone—hematologic cancer	1.58e-05	3.74e-05	CcSEcCtD
Cevimeline—Confusional state—Epirubicin—hematologic cancer	1.57e-05	3.73e-05	CcSEcCtD
Cevimeline—Diarrhoea—Dexamethasone—hematologic cancer	1.57e-05	3.71e-05	CcSEcCtD
Cevimeline—Diarrhoea—Betamethasone—hematologic cancer	1.57e-05	3.71e-05	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—hematologic cancer	1.56e-05	3.7e-05	CcSEcCtD
Cevimeline—Oedema—Epirubicin—hematologic cancer	1.56e-05	3.7e-05	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—hematologic cancer	1.56e-05	3.69e-05	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—hematologic cancer	1.55e-05	3.68e-05	CcSEcCtD
Cevimeline—Infection—Epirubicin—hematologic cancer	1.55e-05	3.67e-05	CcSEcCtD
Cevimeline—Cough—Doxorubicin—hematologic cancer	1.54e-05	3.66e-05	CcSEcCtD
Cevimeline—Shock—Epirubicin—hematologic cancer	1.53e-05	3.64e-05	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—hematologic cancer	1.53e-05	3.63e-05	CcSEcCtD
Cevimeline—Nervous system disorder—Epirubicin—hematologic cancer	1.53e-05	3.62e-05	CcSEcCtD
Cevimeline—Thrombocytopenia—Epirubicin—hematologic cancer	1.53e-05	3.62e-05	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—hematologic cancer	1.53e-05	3.62e-05	CcSEcCtD
Cevimeline—Tachycardia—Epirubicin—hematologic cancer	1.52e-05	3.61e-05	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.52e-05	3.6e-05	CcSEcCtD
Cevimeline—Skin disorder—Epirubicin—hematologic cancer	1.51e-05	3.59e-05	CcSEcCtD
Cevimeline—Dizziness—Betamethasone—hematologic cancer	1.51e-05	3.59e-05	CcSEcCtD
Cevimeline—Dizziness—Dexamethasone—hematologic cancer	1.51e-05	3.59e-05	CcSEcCtD
Cevimeline—Hyperhidrosis—Epirubicin—hematologic cancer	1.51e-05	3.57e-05	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—hematologic cancer	1.51e-05	3.57e-05	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—hematologic cancer	1.5e-05	3.57e-05	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—hematologic cancer	1.5e-05	3.57e-05	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—hematologic cancer	1.5e-05	3.57e-05	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—hematologic cancer	1.5e-05	3.55e-05	CcSEcCtD
Cevimeline—Nausea—Triamcinolone—hematologic cancer	1.5e-05	3.55e-05	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—hematologic cancer	1.5e-05	3.55e-05	CcSEcCtD
Cevimeline—Discomfort—Doxorubicin—hematologic cancer	1.49e-05	3.52e-05	CcSEcCtD
Cevimeline—Anorexia—Epirubicin—hematologic cancer	1.49e-05	3.52e-05	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—hematologic cancer	1.48e-05	3.52e-05	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—hematologic cancer	1.48e-05	3.51e-05	CcSEcCtD
Cevimeline—Hypersensitivity—Prednisone—hematologic cancer	1.47e-05	3.48e-05	CcSEcCtD
Cevimeline—Dyspepsia—Methotrexate—hematologic cancer	1.47e-05	3.48e-05	CcSEcCtD
Cevimeline—Hypotension—Epirubicin—hematologic cancer	1.46e-05	3.45e-05	CcSEcCtD
Cevimeline—Vomiting—Betamethasone—hematologic cancer	1.45e-05	3.45e-05	CcSEcCtD
Cevimeline—Vomiting—Dexamethasone—hematologic cancer	1.45e-05	3.45e-05	CcSEcCtD
Cevimeline—Confusional state—Doxorubicin—hematologic cancer	1.45e-05	3.45e-05	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—hematologic cancer	1.45e-05	3.43e-05	CcSEcCtD
Cevimeline—Rash—Dexamethasone—hematologic cancer	1.44e-05	3.42e-05	CcSEcCtD
Cevimeline—Rash—Betamethasone—hematologic cancer	1.44e-05	3.42e-05	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—hematologic cancer	1.44e-05	3.42e-05	CcSEcCtD
Cevimeline—Dermatitis—Dexamethasone—hematologic cancer	1.44e-05	3.42e-05	CcSEcCtD
Cevimeline—Dermatitis—Betamethasone—hematologic cancer	1.44e-05	3.42e-05	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—hematologic cancer	1.44e-05	3.4e-05	CcSEcCtD
Cevimeline—Headache—Betamethasone—hematologic cancer	1.43e-05	3.4e-05	CcSEcCtD
Cevimeline—Headache—Dexamethasone—hematologic cancer	1.43e-05	3.4e-05	CcSEcCtD
Cevimeline—Infection—Doxorubicin—hematologic cancer	1.43e-05	3.4e-05	CcSEcCtD
Cevimeline—Asthenia—Prednisone—hematologic cancer	1.43e-05	3.39e-05	CcSEcCtD
Cevimeline—Pain—Methotrexate—hematologic cancer	1.42e-05	3.38e-05	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.42e-05	3.37e-05	CcSEcCtD
Cevimeline—Shock—Doxorubicin—hematologic cancer	1.42e-05	3.36e-05	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—hematologic cancer	1.41e-05	3.35e-05	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—hematologic cancer	1.41e-05	3.35e-05	CcSEcCtD
Cevimeline—Pruritus—Prednisone—hematologic cancer	1.41e-05	3.34e-05	CcSEcCtD
Cevimeline—Insomnia—Epirubicin—hematologic cancer	1.41e-05	3.34e-05	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—hematologic cancer	1.41e-05	3.34e-05	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—hematologic cancer	1.4e-05	3.32e-05	CcSEcCtD
Cevimeline—Paraesthesia—Epirubicin—hematologic cancer	1.4e-05	3.32e-05	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—hematologic cancer	1.39e-05	3.31e-05	CcSEcCtD
Cevimeline—Dyspnoea—Epirubicin—hematologic cancer	1.39e-05	3.29e-05	CcSEcCtD
Cevimeline—Somnolence—Epirubicin—hematologic cancer	1.39e-05	3.29e-05	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—hematologic cancer	1.37e-05	3.26e-05	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—hematologic cancer	1.37e-05	3.25e-05	CcSEcCtD
Cevimeline—Dyspepsia—Epirubicin—hematologic cancer	1.37e-05	3.25e-05	CcSEcCtD
Cevimeline—Diarrhoea—Prednisone—hematologic cancer	1.36e-05	3.23e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—hematologic cancer	1.36e-05	3.23e-05	CcSEcCtD
Cevimeline—Nausea—Dexamethasone—hematologic cancer	1.36e-05	3.22e-05	CcSEcCtD
Cevimeline—Nausea—Betamethasone—hematologic cancer	1.36e-05	3.22e-05	CcSEcCtD
Cevimeline—Decreased appetite—Epirubicin—hematologic cancer	1.35e-05	3.21e-05	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—hematologic cancer	1.35e-05	3.2e-05	CcSEcCtD
Cevimeline—Fatigue—Epirubicin—hematologic cancer	1.34e-05	3.19e-05	CcSEcCtD
Cevimeline—Pain—Epirubicin—hematologic cancer	1.33e-05	3.16e-05	CcSEcCtD
Cevimeline—Constipation—Epirubicin—hematologic cancer	1.33e-05	3.16e-05	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—hematologic cancer	1.32e-05	3.14e-05	CcSEcCtD
Cevimeline—Dizziness—Prednisone—hematologic cancer	1.32e-05	3.12e-05	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—hematologic cancer	1.32e-05	3.12e-05	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—hematologic cancer	1.32e-05	3.12e-05	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.31e-05	3.12e-05	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—hematologic cancer	1.3e-05	3.09e-05	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—hematologic cancer	1.29e-05	3.07e-05	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—hematologic cancer	1.29e-05	3.05e-05	CcSEcCtD
Cevimeline—Feeling abnormal—Epirubicin—hematologic cancer	1.28e-05	3.05e-05	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—hematologic cancer	1.28e-05	3.04e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Epirubicin—hematologic cancer	1.27e-05	3.02e-05	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—hematologic cancer	1.27e-05	3.01e-05	CcSEcCtD
Cevimeline—Vomiting—Prednisone—hematologic cancer	1.27e-05	3e-05	CcSEcCtD
Cevimeline—Rash—Prednisone—hematologic cancer	1.26e-05	2.98e-05	CcSEcCtD
Cevimeline—Dermatitis—Prednisone—hematologic cancer	1.26e-05	2.98e-05	CcSEcCtD
Cevimeline—Decreased appetite—Doxorubicin—hematologic cancer	1.25e-05	2.97e-05	CcSEcCtD
Cevimeline—Headache—Prednisone—hematologic cancer	1.25e-05	2.96e-05	CcSEcCtD
Cevimeline—Fatigue—Doxorubicin—hematologic cancer	1.24e-05	2.95e-05	CcSEcCtD
Cevimeline—Urticaria—Epirubicin—hematologic cancer	1.24e-05	2.94e-05	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—hematologic cancer	1.23e-05	2.92e-05	CcSEcCtD
Cevimeline—Pain—Doxorubicin—hematologic cancer	1.23e-05	2.92e-05	CcSEcCtD
Cevimeline—Abdominal pain—Epirubicin—hematologic cancer	1.23e-05	2.92e-05	CcSEcCtD
Cevimeline—Body temperature increased—Epirubicin—hematologic cancer	1.23e-05	2.92e-05	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—hematologic cancer	1.23e-05	2.91e-05	CcSEcCtD
Cevimeline—Asthenia—Methotrexate—hematologic cancer	1.19e-05	2.83e-05	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—hematologic cancer	1.19e-05	2.82e-05	CcSEcCtD
Cevimeline—Nausea—Prednisone—hematologic cancer	1.18e-05	2.81e-05	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.18e-05	2.8e-05	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—hematologic cancer	1.18e-05	2.79e-05	CcSEcCtD
Cevimeline—Hypersensitivity—Epirubicin—hematologic cancer	1.15e-05	2.72e-05	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—hematologic cancer	1.15e-05	2.72e-05	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—hematologic cancer	1.14e-05	2.7e-05	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—hematologic cancer	1.14e-05	2.7e-05	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—hematologic cancer	1.14e-05	2.7e-05	CcSEcCtD
Cevimeline—Asthenia—Epirubicin—hematologic cancer	1.12e-05	2.65e-05	CcSEcCtD
Cevimeline—Pruritus—Epirubicin—hematologic cancer	1.1e-05	2.61e-05	CcSEcCtD
Cevimeline—Dizziness—Methotrexate—hematologic cancer	1.1e-05	2.61e-05	CcSEcCtD
Cevimeline—Diarrhoea—Epirubicin—hematologic cancer	1.07e-05	2.53e-05	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—hematologic cancer	1.06e-05	2.52e-05	CcSEcCtD
Cevimeline—Vomiting—Methotrexate—hematologic cancer	1.06e-05	2.51e-05	CcSEcCtD
Cevimeline—Rash—Methotrexate—hematologic cancer	1.05e-05	2.49e-05	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—hematologic cancer	1.05e-05	2.49e-05	CcSEcCtD
Cevimeline—Headache—Methotrexate—hematologic cancer	1.04e-05	2.47e-05	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—hematologic cancer	1.03e-05	2.45e-05	CcSEcCtD
Cevimeline—Dizziness—Epirubicin—hematologic cancer	1.03e-05	2.44e-05	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—hematologic cancer	1.02e-05	2.42e-05	CcSEcCtD
Cevimeline—Vomiting—Epirubicin—hematologic cancer	9.91e-06	2.35e-05	CcSEcCtD
Cevimeline—Nausea—Methotrexate—hematologic cancer	9.89e-06	2.35e-05	CcSEcCtD
Cevimeline—Diarrhoea—Doxorubicin—hematologic cancer	9.87e-06	2.34e-05	CcSEcCtD
Cevimeline—Rash—Epirubicin—hematologic cancer	9.83e-06	2.33e-05	CcSEcCtD
Cevimeline—Dermatitis—Epirubicin—hematologic cancer	9.82e-06	2.33e-05	CcSEcCtD
Cevimeline—Headache—Epirubicin—hematologic cancer	9.76e-06	2.32e-05	CcSEcCtD
Cevimeline—Dizziness—Doxorubicin—hematologic cancer	9.53e-06	2.26e-05	CcSEcCtD
Cevimeline—Nausea—Epirubicin—hematologic cancer	9.26e-06	2.2e-05	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—hematologic cancer	9.17e-06	2.17e-05	CcSEcCtD
Cevimeline—Rash—Doxorubicin—hematologic cancer	9.09e-06	2.16e-05	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—hematologic cancer	9.08e-06	2.15e-05	CcSEcCtD
Cevimeline—Headache—Doxorubicin—hematologic cancer	9.03e-06	2.14e-05	CcSEcCtD
Cevimeline—Nausea—Doxorubicin—hematologic cancer	8.56e-06	2.03e-05	CcSEcCtD
Cevimeline—CYP2D6—Metabolism—ABCG2—hematologic cancer	8.53e-06	0.000195	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCL2—hematologic cancer	8.49e-06	0.000194	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AGRN—hematologic cancer	8.49e-06	0.000194	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6R—hematologic cancer	8.46e-06	0.000193	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCL2—hematologic cancer	8.46e-06	0.000193	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6R—hematologic cancer	8.44e-06	0.000192	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO2—hematologic cancer	8.37e-06	0.000191	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3R1—hematologic cancer	8.33e-06	0.00019	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3R1—hematologic cancer	8.31e-06	0.000189	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTT1—hematologic cancer	8.12e-06	0.000185	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—JAK2—hematologic cancer	8.1e-06	0.000185	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—JAK2—hematologic cancer	8.07e-06	0.000184	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAP2K1—hematologic cancer	8.07e-06	0.000184	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HMMR—hematologic cancer	8.05e-06	0.000183	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—IDH2—hematologic cancer	8.05e-06	0.000183	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAP2K1—hematologic cancer	8.04e-06	0.000183	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GRB2—hematologic cancer	8.03e-06	0.000183	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CD—hematologic cancer	8.01e-06	0.000183	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PDGFA—hematologic cancer	8.01e-06	0.000183	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GRB2—hematologic cancer	8e-06	0.000182	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CD—hematologic cancer	7.99e-06	0.000182	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PDGFA—hematologic cancer	7.98e-06	0.000182	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SDC1—hematologic cancer	7.93e-06	0.000181	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KITLG—hematologic cancer	7.89e-06	0.00018	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KITLG—hematologic cancer	7.87e-06	0.000179	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STAT5A—hematologic cancer	7.71e-06	0.000176	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CB—hematologic cancer	7.69e-06	0.000175	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STAT5A—hematologic cancer	7.69e-06	0.000175	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CB—hematologic cancer	7.67e-06	0.000175	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN2B—hematologic cancer	7.65e-06	0.000174	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MTHFR—hematologic cancer	7.64e-06	0.000174	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN2B—hematologic cancer	7.62e-06	0.000174	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3R1—hematologic cancer	7.57e-06	0.000173	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.57e-06	0.000173	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3R1—hematologic cancer	7.54e-06	0.000172	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CD86—hematologic cancer	7.4e-06	0.000169	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CD86—hematologic cancer	7.37e-06	0.000168	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CA9—hematologic cancer	7.36e-06	0.000168	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ACP5—hematologic cancer	7.36e-06	0.000168	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—JAK2—hematologic cancer	7.35e-06	0.000168	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—JAK2—hematologic cancer	7.33e-06	0.000167	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HES1—hematologic cancer	7.29e-06	0.000166	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HES1—hematologic cancer	7.27e-06	0.000166	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NCOR2—hematologic cancer	7.26e-06	0.000166	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NCOR1—hematologic cancer	7.25e-06	0.000165	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NCOR1—hematologic cancer	7.23e-06	0.000165	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGF1—hematologic cancer	7.17e-06	0.000163	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CSF2—hematologic cancer	7.17e-06	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CSF2—hematologic cancer	7.15e-06	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGF1—hematologic cancer	7.15e-06	0.000163	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FOXO1—hematologic cancer	7.07e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2—hematologic cancer	7.06e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PDGFRB—hematologic cancer	7.05e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FOXO1—hematologic cancer	7.04e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2—hematologic cancer	7.04e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PDGFRB—hematologic cancer	7.03e-06	0.00016	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CB—hematologic cancer	6.99e-06	0.000159	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CB—hematologic cancer	6.96e-06	0.000159	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PDGFRA—hematologic cancer	6.95e-06	0.000158	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PDGFRA—hematologic cancer	6.92e-06	0.000158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JAK1—hematologic cancer	6.92e-06	0.000158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PRKCG—hematologic cancer	6.92e-06	0.000158	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—IDH1—hematologic cancer	6.92e-06	0.000158	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PRKCG—hematologic cancer	6.9e-06	0.000157	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JAK1—hematologic cancer	6.9e-06	0.000157	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.84e-06	0.000156	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TXN—hematologic cancer	6.84e-06	0.000156	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.84e-06	0.000156	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CD44—hematologic cancer	6.74e-06	0.000154	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NQO1—hematologic cancer	6.74e-06	0.000154	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.7e-06	0.000153	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	6.46e-06	0.000147	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2RA—hematologic cancer	6.44e-06	0.000147	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—UGT1A1—hematologic cancer	6.43e-06	0.000147	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CG—hematologic cancer	6.42e-06	0.000146	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2—hematologic cancer	6.41e-06	0.000146	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2—hematologic cancer	6.39e-06	0.000146	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TERT—hematologic cancer	6.39e-06	0.000146	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYCS—hematologic cancer	6.38e-06	0.000145	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TERT—hematologic cancer	6.37e-06	0.000145	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	6.34e-06	0.000145	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CRABP1—hematologic cancer	6.26e-06	0.000143	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC22A1—hematologic cancer	6.26e-06	0.000143	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	6.24e-06	0.000142	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	6.22e-06	0.000142	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALOX5—hematologic cancer	6.1e-06	0.000139	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TSC2—hematologic cancer	6.1e-06	0.000139	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TSC2—hematologic cancer	6.08e-06	0.000139	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CREBBP—hematologic cancer	5.95e-06	0.000136	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NUP98—hematologic cancer	5.91e-06	0.000135	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	5.87e-06	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	5.85e-06	0.000133	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	5.81e-06	0.000132	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	5.79e-06	0.000132	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.73e-06	0.000131	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.73e-06	0.000131	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ESR1—hematologic cancer	5.7e-06	0.00013	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NUP214—hematologic cancer	5.69e-06	0.00013	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ESR1—hematologic cancer	5.68e-06	0.000129	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CD—hematologic cancer	5.64e-06	0.000129	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FN1—hematologic cancer	5.63e-06	0.000128	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTP1—hematologic cancer	5.63e-06	0.000128	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FN1—hematologic cancer	5.61e-06	0.000128	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.58e-06	0.000127	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTR—hematologic cancer	5.58e-06	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALB—hematologic cancer	5.57e-06	0.000127	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BAD—hematologic cancer	5.56e-06	0.000127	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	5.56e-06	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BAD—hematologic cancer	5.54e-06	0.000126	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	5.54e-06	0.000126	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	5.51e-06	0.000126	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	5.49e-06	0.000125	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO2—hematologic cancer	5.47e-06	0.000125	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CD80—hematologic cancer	5.39e-06	0.000123	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KIT—hematologic cancer	5.39e-06	0.000123	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	5.39e-06	0.000123	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	5.39e-06	0.000123	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CD80—hematologic cancer	5.38e-06	0.000123	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	5.37e-06	0.000122	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KIT—hematologic cancer	5.37e-06	0.000122	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	5.37e-06	0.000122	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3R1—hematologic cancer	5.33e-06	0.000121	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ABCB1—hematologic cancer	5.32e-06	0.000121	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.31e-06	0.000121	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	5.29e-06	0.000121	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	5.27e-06	0.00012	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SDC1—hematologic cancer	5.19e-06	0.000118	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTM1—hematologic cancer	5.17e-06	0.000118	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NCOR1—hematologic cancer	5.17e-06	0.000118	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	5.16e-06	0.000118	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	5.14e-06	0.000117	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CREB1—hematologic cancer	5.13e-06	0.000117	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CREB1—hematologic cancer	5.11e-06	0.000116	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BRAF—hematologic cancer	5.06e-06	0.000115	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BRAF—hematologic cancer	5.05e-06	0.000115	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCL2—hematologic cancer	5.02e-06	0.000114	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6R—hematologic cancer	5e-06	0.000114	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCL2—hematologic cancer	5e-06	0.000114	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	4.99e-06	0.000114	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6R—hematologic cancer	4.98e-06	0.000114	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	4.98e-06	0.000113	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CB—hematologic cancer	4.92e-06	0.000112	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	4.77e-06	0.000109	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	4.75e-06	0.000108	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	4.73e-06	0.000108	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	4.72e-06	0.000108	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.69e-06	0.000107	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	4.67e-06	0.000107	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	4.63e-06	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	4.62e-06	0.000105	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.57e-06	0.000104	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGF2—hematologic cancer	4.53e-06	0.000103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGF2—hematologic cancer	4.52e-06	0.000103	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	4.47e-06	0.000102	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	4.46e-06	0.000102	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CD44—hematologic cancer	4.41e-06	0.000101	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NQO1—hematologic cancer	4.41e-06	0.000101	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JAK2—hematologic cancer	4.34e-06	9.9e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JAK2—hematologic cancer	4.33e-06	9.87e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	4.26e-06	9.71e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTEN—hematologic cancer	4.25e-06	9.69e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	4.24e-06	9.68e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MDM2—hematologic cancer	4.24e-06	9.67e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MDM2—hematologic cancer	4.23e-06	9.64e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYCS—hematologic cancer	4.17e-06	9.51e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.15e-06	9.45e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MTOR—hematologic cancer	4.13e-06	9.41e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	4.13e-06	9.41e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MTOR—hematologic cancer	4.11e-06	9.38e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	4.11e-06	9.38e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—EP300—hematologic cancer	4.05e-06	9.24e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	3.94e-06	8.98e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	3.93e-06	8.95e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	3.87e-06	8.83e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	3.86e-06	8.8e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.84e-06	8.75e-05	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	3.83e-06	8.73e-05	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	3.82e-06	8.71e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CASP3—hematologic cancer	3.8e-06	8.65e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2—hematologic cancer	3.79e-06	8.64e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CASP3—hematologic cancer	3.78e-06	8.62e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2—hematologic cancer	3.78e-06	8.61e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6—hematologic cancer	3.77e-06	8.6e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6—hematologic cancer	3.76e-06	8.57e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—hematologic cancer	3.69e-06	8.42e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUN—hematologic cancer	3.69e-06	8.4e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—hematologic cancer	3.68e-06	8.4e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.68e-06	8.38e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUN—hematologic cancer	3.67e-06	8.38e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	3.57e-06	8.15e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTEN—hematologic cancer	3.57e-06	8.13e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	3.56e-06	8.12e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.56e-06	8.11e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTEN—hematologic cancer	3.55e-06	8.1e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	3.49e-06	7.95e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.48e-06	7.94e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	3.48e-06	7.93e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	3.48e-06	7.93e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	3.47e-06	7.91e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EP300—hematologic cancer	3.4e-06	7.75e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EP300—hematologic cancer	3.39e-06	7.73e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.38e-06	7.71e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.38e-06	7.71e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.37e-06	7.69e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALB—hematologic cancer	3.33e-06	7.59e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SRC—hematologic cancer	3.31e-06	7.54e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SRC—hematologic cancer	3.3e-06	7.51e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	3.22e-06	7.34e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	3.21e-06	7.32e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STAT3—hematologic cancer	3.19e-06	7.27e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.19e-06	7.26e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NRAS—hematologic cancer	3.18e-06	7.25e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STAT3—hematologic cancer	3.18e-06	7.25e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NRAS—hematologic cancer	3.17e-06	7.23e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	3.05e-06	6.95e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	3.04e-06	6.92e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CA—hematologic cancer	3e-06	6.84e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.99e-06	6.81e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—hematologic cancer	2.96e-06	6.76e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	2.96e-06	6.74e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—hematologic cancer	2.95e-06	6.73e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	2.95e-06	6.72e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.94e-06	6.71e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KRAS—hematologic cancer	2.74e-06	6.24e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KRAS—hematologic cancer	2.73e-06	6.22e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTEN—hematologic cancer	2.54e-06	5.79e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.52e-06	5.73e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.51e-06	5.72e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	2.51e-06	5.72e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—AKT1—hematologic cancer	2.45e-06	5.58e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.43e-06	5.55e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—hematologic cancer	2.43e-06	5.53e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—EP300—hematologic cancer	2.42e-06	5.53e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.33e-06	5.31e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.33e-06	5.3e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HRAS—hematologic cancer	2.32e-06	5.29e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6—hematologic cancer	2.23e-06	5.08e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6—hematologic cancer	2.22e-06	5.06e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.21e-06	5.03e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALB—hematologic cancer	2.18e-06	4.97e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.08e-06	4.75e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKT1—hematologic cancer	2.05e-06	4.68e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKT1—hematologic cancer	2.05e-06	4.67e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.92e-06	4.38e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.79e-06	4.09e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTEN—hematologic cancer	1.66e-06	3.79e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—EP300—hematologic cancer	1.58e-06	3.61e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—AKT1—hematologic cancer	1.46e-06	3.34e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.17e-06	2.67e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AKT1—hematologic cancer	9.58e-07	2.18e-05	CbGpPWpGaD
